Susan Hahn

AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent and demonstrates efficacy in combination therapy

AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models

Human chimeric anti-CD44 antibody ARH460–16–2 binds leukemic cells and malignant plasma cells

Clinical development of huARH460-16-2: A therapeutic antibody targeting the CD44 cancer stem cell antigen on high-incidence adenocarcinomas

AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models

371 POSTER Toxicology and pharmacokinetics of humanized AR47A6.4.2, the first unconjugated therapeutic monoclonal antibody targeting TROP-2

538 POSTER ARH460-16-2, targeting the CD44 cancer stem cell marker, uses multiple mechanisms to achieve its therapeutic anti-cancer effects

543 POSTER Location… location… location: hitting the functional epitope within the target is essential for anti-cancer antibody therapeutics

A monoclonal antibody targeting melanoma-associated chondroitin sulfate proteoglycan demonstrates antitumor activity in human melanoma, ovarian and breast cancer models.

Toxicology and pharmacokinetics of chimeric ARH460-16-2, a therapeutic monoclonal antibody targeting CD44